Alembic Pharmaceuticals Ltd Share Price (APLLTD)
as on
| Source : NSE
Alembic Pharmaceuticals Ltd Stock Performance
as on August 14, 2025 at 4:01 PM IST
Day's Low
Day's High
₹941.6₹979
1.60%
Downside
2.30%
Upside
52 Week's Low
52 Week's High
₹725.2₹1,303.924.22%
Downside
36.26%
Upside
| Market Stats | |
| Previous Close | ₹942.75 |
| Open | ₹943.05 |
| Volume | 2.02L |
| Upper Circuit | ₹1,131.30 |
| Lower Circuit | ₹754.20 |
| Day's Low | ₹941.6 |
| Day's High | ₹979 |
| 52 Week Low | ₹725.2 |
| 52 Week High | ₹1,303.9 |
| Returns % | |
| 1 Month Return | -7.14 % |
| 3 Month Return | + 4.64 % |
| 1 Year Return | -12.16 % |
| 3 Year Return | + 45.39 % |
| 5 Year Return | -4.38 % |
Alembic Pharmaceuticals Ltd Stock Fundamentals & Key Indicators
Check Alembic Pharmaceuticals Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹18,810.11 Cr
Return on Equity (ROE)
9.96
PE Ratio (TTM)
31.24
Return on capital employed (ROCE)
11.4
Industry PE ratio
43.28
Beta (LTM)
0.53
P/B Ratio
3.52
Dividend Yield
1.18
PEG Ratio
-21.4
Quarterly Earnings Growth YOY
14.19
EPS (TTM)
29.61
Sector
Pharmaceuticals
Book Value
264.1
Technical Analysis
Bearish
View Technical Analysis
Alembic Pharmaceuticals Ltd Stock's Interest Amongst Investors
Alembic Pharmaceuticals Ltd Stock Valuation
Track how Alembic Pharmaceuticals Ltd P/E has moved over time to understand its valuation trends.
Alembic Pharmaceuticals Ltd in the last 5 years
Lowest (11.53x)
March 23, 2020
Today (31.24x)
August 14, 2025
Industry (43.28x)
August 14, 2025
Highest (53.41x)
January 3, 2023
Today’s Price to Earnings Ratio: 31.24x
Alembic Pharmaceuticals Ltd Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Alembic Pharmaceuticals Ltd.
based on 11 analysts
63.64%
Buy
36.36%
Hold
0.00%
Sell
63.64% of analysts recommend a 'BUY' rating for Alembic Pharmaceuticals Ltd. Average target price of ₹1058.36
Source: S&P Global Market Intelligence
Alembic Pharmaceuticals Ltd Share Price Target
Get share price movements and forecasts by analysts on Alembic Pharmaceuticals Ltd.
Alembic Pharmaceuticals Ltd price forecast by 11 analysts
Upside of10.60%
High
₹1345
Target
₹1058.36
Low
₹900
Alembic Pharmaceuticals Ltd target price ₹1058.36, a slight upside of 10.6% compared to current price of ₹956.95. According to 11 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Alembic Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2027:22.26%
Forecast
Actual
Including amortisation and stock based compensations
Alembic Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2027:54.68%
Forecast
Actual
Source: S&P Global Market Intelligence
Alembic Pharmaceuticals Ltd Financial Results
Get the annual and quarterly financial summary of Alembic Pharmaceuticals Ltd, including revenue, profit, loss and more.
Alembic Pharmaceuticals Ltd Earnings and Dividends
View detailed summary of the earnings and dividend history of Alembic Pharmaceuticals Ltd.
Alembic Pharmaceuticals Ltd Earnings Results
Alembic Pharmaceuticals Ltd’s net profit jumped 14.6% since last year same period to ₹154.38Cr in the Q1 2025-2026. On a quarterly growth basis, Alembic Pharmaceuticals Ltd has generated -1.6% fall in its net profits since last 3-months.
Read More about Earnings ResultsAlembic Pharmaceuticals Ltd Dividends May,2025
In the quarter ending March 2025, Alembic Pharmaceuticals Ltd has declared dividend of ₹11.00 per share on 06 May 2025 - translating a dividend yield of 2.30%.
Read More about Dividends
Indices Featuring Alembic Pharmaceuticals Ltd Stock
Check stock indices that include Alembic Pharmaceuticals Ltd.
Alembic Pharmaceuticals Ltd Stock Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Alembic Pharmaceuticals Ltd.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 69.67% | 0.01 | |
| Foreign Institutions | 3.96% | 0.46 | |
| Mutual Funds | 9.05% | ||
| Retail Investors | 9.9% | ||
| Others | 7.41% | 2.40 |
Alembic Pharmaceuticals Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Alembic Pharmaceuticals Ltd with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 18,810.11 | -0.88% | 0.61 | 582 | 6,672 | |
| BUY | 11,690.03 | -7.88% | 0.52 | 413 | 2,013 | |
| BUY | 63,492.31 | 5.11% | 0.59 | 3,168 | 29,001 | |
| HOLD | 99,496.42 | 29.75% | 0.61 | 4,614 | 23,241 | |
| BUY | 70,688.13 | 19.9% | 0.00 | 1,414 | 6,445 |
Alembic Pharmaceuticals Ltd News & Key Events
Latest news and events in one place to help you make informed investing decisions in Alembic Pharmaceuticals Ltd.
Alembic Pharma Receives Mixed Ratings Amid Q1 Results - 06 Aug, 2025
Alembic Pharmaceuticals sees varied analyst ratings following Q1FY26 results, with Antique raising its target to ₹1,275 and ICICI maintaining a Hold at ₹900. The company is focusing on US generics while preparing for potential tariffs. Despite a 3% dip post-results, revenue growth was noted in international markets.Alembic Pharma Reports Strong Q1 Earnings Growth - 05 Aug, 2025
Alembic Pharmaceuticals announced a 14% increase in Q1 net profit to ₹154 crore, supported by robust sales in both India and the US markets. Total income rose to ₹1,717 crore, reflecting strong performance across various segments despite ongoing pricing pressures. The company launched new products and secured ANDA approvals, indicating a positive outlook for future growth.Alembic Pharmaceuticals Gains USFDA Approval, Shares Surge - 28 Jul, 2025
Alembic Pharmaceuticals secured USFDA approval for its generic Carbamazepine extended-release tablets, leading to a 2% surge in shares. The stock is also in focus for upcoming dividend eligibility.Alembic Pharma Secures USFDA Approval for Carbamazepine - 26 Jul, 2025
Alembic Pharmaceuticals has received final USFDA approval for Carbamazepine Extended-Release Tablets, a generic version of Tegretol-XR, with a market size of $71 million.
Insights on Alembic Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 7 days, APLLTD stock has moved up by 2.2%
- POSITIVE IMPACT
Promoter Holding Up
Promoters have increased holdings from 69.67% to 69.68% in Jun 2025 quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 3.94% to 3.96% in Jun 2025 quarter
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 130.2% return, outperforming this stock by 84.8%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 32.3% return, outperforming this stock by 44.5%
NEGATIVE IMPACTProfit Down
Netprofit is down for the last 2 quarters, 156.89 Cr → 154.38 Cr (in ₹), with an average decrease of 1.6% per quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 9.96% to 9.90% in Jun 2025 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 9.20% to 9.05% in Jun 2025 quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 1.78K Cr → 1.71K Cr (in ₹), with an average decrease of 3.7% per quarter
About Alembic Pharmaceuticals Ltd
Revenue: ₹1,710.72Cr as on June 2025 (Q1 FY26)
Net Profit: ₹153.63Cr as on June 2025 (Q1 FY26)
Listing date: 20 Sep, 2011
Chairperson Name: Chirayu R Amin
| Organisation | Alembic Pharmaceuticals Ltd |
| Headquarters | Vadodara |
| Industry | Pharmaceuticals |
| CEO | Chirayu R Amin |
| E-voting on shares | Click here to vote |
Mutual Funds that own Alembic Pharmaceuticals Ltd Stock
Check out the Mutual Funds with significant holdings in Alembic Pharmaceuticals Ltd.
| Funds | Holdings | Prev. 5M |
|---|---|---|
| Kotak Small Cap Direct Growth | 1.87% | |
| DSP Midcap Fund Direct Plan Growth | 1.5% | |
| DSP Small Cap Fund Direct Plan Growth | 0.86% | |
| Axis Small Cap Fund Direct Growth | 0.54% | |
| DSP ELSS Tax Saver Fund Direct Plan Growth | 0.83% |
FAQs
What is Alembic Pharmaceuticals Ltd share price today?
Alembic Pharmaceuticals Ltd share price today stands at ₹956.95, Open: ₹943.05, Previous Close: ₹942.75, High: ₹979, Low: ₹941.6, 52 Week High: ₹1303.9, 52 Week Low: ₹725.2 as on .
How to buy Alembic Pharmaceuticals Ltd shares ?
To buy Alembic Pharmaceuticals Ltd shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for APLLTD or Alembic Pharmaceuticals Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Alembic Pharmaceuticals Ltd shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is today's traded volume of Alembic Pharmaceuticals Ltd?
Today's traded volume of Alembic Pharmaceuticals Ltd is 2.02L. Which means that 2.02L shares of Alembic Pharmaceuticals Ltd were bought and sold on the stock market during today's trading session.
What is Alembic Pharmaceuticals Ltd's market cap today?
Today's market capitalisation of Alembic Pharmaceuticals Ltd is ₹18,810.11 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Alembic Pharmaceuticals Ltd?
Alembic Pharmaceuticals Ltd’s 52 week high is ₹1303.9 and 52 week low is ₹725.2. The current share price of Alembic Pharmaceuticals Ltd is ₹956.95, which is -26.61% down from its 52 week high and 31.96% up from its 52 week low.